Role of Fibirnogen Like Protein 2 as Aprognostic Factor in High Grade Glioma

Brain Tumor Adult Clinical Trial

Official title:

Role of Fibirnogen Like Protein 2 as Aprognostic Factor in High Grade Glioma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04113278
• Other study ID #: FGL2 in brain cancer
• Status: Not yet recruiting
• Start date: November 1, 2019
• Est. completion date: September 1, 2021

Study information

• Verified date: October 2019
• Source: Assiut University
• Contact: samir shehata, professor
• Phone: 01222302375
• Email: Samir-eid[@]Hotmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study population was selected from high grade glioma pateints attending the Department of Clinical Oncology, Assiut University hospital during the period from December 2018 to September 2020, we analyzed human high grade gliomas paraffin block for FLG2 expression

Description:

Glioblastoma is the most common malignant primary brain tumor in adults, and despite aggressive treatment, it is incurable Patient prognosis differs considerably within the different World Health Organization (WHO) grades, poorest prognosis for patients with the grade IV tumour- the glioblastoma multiform (GBM).

Fibrinogen-like protein 2 (FGL2),regulates both innate and adaptive immunity. FGL2 is a 439 amino acid secreted protein that is similar to the β- and γ-chains of fibrinogen.

Secreted FGL2 (sFGL2) is the key regulator in immunosuppression may play important role in malignant transformation of low to high by inhibiting the proliferation of T cell Study the role of fibrinogen-like protein2 on Immunosuppression and progression ，free survival and overall survival in high grade glioma

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1
• Est. completion date: September 1, 2021
• Est. primary completion date: September 1, 2020
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Pateints>18 years old

• Pathologically proven high grade glioma

• Total or subtotal resection of the tumor

• Patients received concurrent radiation therapy with temozolomide followed by adjuvant temozolamide for 6 months

Exclusion Criteria:

• Pregnancy

• Breast feeding

• Other comorbidity

• Previous malignancy or radiation therapy or chemotherapy

Related Conditions & MeSH terms

• Brain Tumor Adult

Intervention

Genetic:
• FGL2 immunohisyochemistry
Correlation between FLG2 expression and progression free survival and overall surviv

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
sohaila Essam

References & Publications (2)

Latha K, Yan J, Yang Y, Gressot LV, Kong LY, Manyam G, Ezhilarasan R, Wang Q, Sulman EP, Eric Davis R, Huang S, Fuller GN, Rao A, Heimberger AB, Li S, Rao G. The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma. J Natl Cancer Inst. 2019 Mar 1;111(3):292-300. doi: 10.1093/jnci/djy107. — View Citation

Yan J, Zhao Q, Gabrusiewicz K, Kong LY, Xia X, Wang J, Ott M, Xu J, Davis RE, Huo L, Rao G, Sun SC, Watowich SS, Heimberger AB, Li S. FGL2 promotes tumor progression in the CNS by suppressing CD103(+) dendritic cell differentiation. Nat Commun. 2019 Jan 25;10(1):448. doi: 10.1038/s41467-018-08271-x. Erratum in: Nat Commun. 2019 Feb 15;10(1):862. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rple of FGL2in high grade glioma as aprognostic factor	Correlation between FLG2 expression and progression free survival and overall survival	baseline